title: Men's sexual response to female partner's intranasal oxytocin administration for hypoactive sexual desire disorder: an open prospective cohort study.
abstract: OBJECTIVE
  To study sexual function, quality of life, and depression in men, whose female partners are undergoing double-blind placebo-controlled randomized treatment for hypoactive sexual desire disorder (HSDD).
  
  
  METHODS
  Open prospective cohort study of 22 weeks.
  
  
  METHODS
  Academic medical center.
  
  
  METHODS
  Male partners of 30 premenopausal and postmenopausal women with HSDD.
  
  
  METHODS
  Baseline, 3-month, and 5-month assessment (for 8 weeks each) of male response to female partner's use of oxytocin nasal spray (32 IE) and placebo within 50 minutes before sexual intercourse.
  
  
  METHODS
  Primary outcome parameters were Sexual Life Quality Questionnaire-Male, Sexual Activity Record, Partner Performance Questionnaire, and Hamilton Depression Scale.
  
  
  RESULTS
  Male Sexual Life Quality questionnaire improved significantly from -7.4 ± 9.9 at baseline to 8.2 ± 12 with female partners' treatment with oxytocin nasal spray and to 10.8 ± 13.8 with placebo. Frequency of intercourse improved slightly but not significantly from 6.3 ± 3.9 at baseline to 7.3 ± 4 with female oxytocin therapy, but not with placebo. Male desire and arousal remained stable throughout the study period. Evaluation of female partners' performance by men improved significantly from 8.9 ± 2.8 at baseline to 10.6 ± 2.2 with oxytocin and to 11.2 ± 2.6 with placebo.
  
  
  CONCLUSIONS
  Female treatment with either oxytocin or placebo for HSDD significantly improves male sexual quality of life and evaluation of female partner's sexual performance with no difference between oxytocin and placebo on any outcome parameters. A nonsignificant improvement was seen in the frequency of intercourse, male arousal, desire, satisfaction, and Hamilton depression scale.
  
  
  BACKGROUND
  NCT02229721.
authors.affiliation: Department of Obstetrics and Gynecology, Medical University of Vienna, Vienna, Austria.
authors.forename: Dana A
authors.initials: DA
authors.lastname: Muin
authors.affiliation: Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
authors.forename: Safoura
authors.initials: S
authors.lastname: Sheikh Rezaei
authors.affiliation: Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
authors.forename: Max
authors.initials: M
authors.lastname: Tremmel-Scheinost
authors.affiliation: Department of Thoracic Surgery, Otto-Wagner-Spital, Vienna, Austria.
authors.forename: Mohamed
authors.initials: M
authors.lastname: Salama
authors.affiliation: University Clinic of Internal Medicine III, Department of Endocrinology and Metabolism, Medical University of Vienna, Vienna, Austria.
authors.forename: Anton
authors.initials: A
authors.lastname: Luger
authors.affiliation: Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
authors.forename: Michael
authors.initials: M
authors.lastname: Wolzt
authors.affiliation: Department of Obstetrics and Gynecology, Medical University of Vienna, Vienna, Austria.
authors.forename: Peter W
authors.initials: PW
authors.lastname: Husslein
authors.affiliation: University Clinic of Internal Medicine III, Department of Endocrinology and Metabolism, Medical University of Vienna, Vienna, Austria. Electronic address: Michaela.Bayerle-Eder@meduniwien.ac.at.
authors.forename: Michaela
authors.initials: M
authors.lastname: Bayerle-Eder
mesh_terms: D000046:Academic Medical Centers; D000280:Administration, Inhalation; D001317:Austria; D018592:Cross-Over Studies; D003863:Depression / Q000175:diagnosis / Q000523:psychology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010121:Oxytocin / Q000008:administration & dosage* / Q000009:adverse effects; D011446:Prospective Studies; D011569:Psychiatric Status Rating Scales; D011788:Quality of Life; D012725:Sexual Behavior / Q000187:drug effects*; D020018:Sexual Dysfunctions, Psychological / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D012747:Sexual Partners / Q000523:psychology*; D011795:Surveys and Questionnaires; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D010121:Oxytocin
keywords: Male sexual function; hypoactive sexual desire disorder; oxytocin; quality of life